Anthony Rothschild, MD, professor of psychiatry, talks about the impact fluoxetine has had on patients with depression.
UMass Medical School was one of several organizations to participate in a job fair at Centro Inc. for hurricane evacuees from Puerto Rico.
An article about using social determinants to calculate health costs includes a quote from Arlene Ash, PhD, professor of quantitative health sciences, who developed a payment formula to begin the process.
Robert H. Brown Jr., DPhil, MD, the Leo P. and Theresa M. LaChance Chair in Medical Research and chair and professor of neurology, along with collaborators at Wave Life Sciences Ltd., discusses the potential for gene editing techniques such as AAV and CRISPR to treat ALS.
Heidi L. Smith, MD, PhD, associate professor of medicine and director of clinical affairs at MassBiologics of UMass Medical School, discusses work by MassBiologics to produce a new diphtheria serum using a monoclonal antibody.
Robert H. Brown Jr., DPhil, MD, the Leo P. and Theresa M. LaChance Chair in Medical Research and chair and professor of neurology, along with collaborators at Wave Life Sciences Ltd., announced data from preclinical studies of WVE-3972-01, the company’s investigational therapeutic for amyotrophic lateral sclerosis and frontotemporal dementia.
A story about the high cost of drugs for treating orphan diseases references work done by former UMass Medical School faculty member Ravindra Singh that led to the development of Spinraza, a drug that treats the cause of spinal muscular atrophy.
Neil Aronin, MD, the Higgins Family Professor of Neuroscience, professor of medicine and co-director of the Neurotherapeutics Institute, discusses his research using gene silencing technology to potentially treat Huntington’s disease.